Is the innovation wave real? Europe's payers' view

Cheap medicines, fast access, strong pharma: can Europe have all three?

Pharma is modelling the P&L instead of launching. Patients are waiting.

MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare.

Europe Can't Pay More For Innovation (and China Isn't Waiting)

Europe Is Losing Access to New Medicines. Here’s Why.

Borderline Products: Turning Regulations into a Strategic Advantage

[EN] - From managing global subsidiaries to walking the talk : when execution becomes personal

[EN] - Biotech survival and resource allocation : why execution is about choosing what not to do

[EN] - Trusting the ground : navigating volatility, growth and partnerships across the EEMEA zone

[EN] - The Chinese pharma ecosystem : balancing systemic scale and constant reinvention

[EN] - Transforming Vidal : how a 20-year vision turned a paper book into digital infrastructure

Groupements de pharmacies : transparence ou soupçon ?

Prevention: These health innovations could prevent thousands of hospitalizations

2050: 1 in 3 French people will be over 60 (are we ready?)

[EN] - Beyond price: why Europe must rescue its essential medicines

[EN] - Price vs. value: The affordability crisis in pharmaceutical innovation

[EN] - How to fix Europe's access gap in Biopharma

[EN] - Why cutting-edge AI research doesn't scale by itself ?

[EN] - The global genomics race: Who is winning?

We were days away from bankruptcy. Until THIS happened...

Why freelance recruitment in the pharmaceutical industry will explode in 2026

Lever ou mourir : les décisions que les CEO biotech ne peuvent plus éviter

The doctor of 2026 no longer wants to be a mere prescriber.

How China is Inventing the Future of Healthcare: AI, Virtual Hospitals, and Pharma Sovereignty

How will headhunters identify healthcare LEADERS in 2025?

Why avoiding risk is the most dangerous move in your pharma career

The 72 Hours that SAVED a biotech from BANKRUPTCY

Du diagnostic au traitement : le rôle du DISPOSITIF MÉDICAL dans la transformation de la santé

Covid, threats, and FAKE NEWS: a scientist speaks out

Why Europe can’t access these 100 new drugs (and how to change it)

What if pharma became CITIZEN again?

Data & ROI - Betting on measuring the value produced for the ecosystem

6-figure fine: A costly MISTAKE (health data)

Courage + Authenticity = The Keys to Delphine Pagano's Leadership, GM of Bayer Pharma France

Entre l’État et l’industrie, elle invente un 3e chemin

Face aux crises, il transforme l’hôpital en acteur du changement

How to lead and reinvent yourself in a disrupted world

Debate: What if saving money in healthcare costs us more than we think?

How to Turn Pharmaceutical Regulation Into a Strategic Advantage

Genetics and Prevention: A Silent Revolution

Ruptures de stock : Quand contrainte réglementaire devient opportunité stratégique pour la pharma

Essential medicines: LXO's strategy for local and sustainable production

Oncologie : le tsunami de la médecine nucléaire, avec Dr Clément Bailly

Groupements de pharmacies : pourquoi un amendement visait à les interdire ?

Responsabilité sociétale et pharma : Les dessous d’un modèle à réinventer, avec Nathalie Gimenes

Assurance Maladie : peut-on encore innover ? Avec Marguerite Cazeneuve

Why healthcare needs bold leaders and collective action - Insights from Julie Puype

URGO Scandal: 55 MILLION EUROS in illegal kickbacks and 8,000 pharmacists involved

80% of cardiovascular diseases are preventable: taking action for women's health

VIDAL : Assister le médecin dans ses décisions les plus essentielles - Vincent Bouvier

Maladies ultra-rares, 1 médicament pour 1 patient - Terence Beghyn CEO Fondateur APTEEUS

2 500 experts pour bâtir un leader du conseil en santé - Julie Marion, COO Efor

Prothèse de genou en ambulatoire, 10 ans d'expérience - Dr Xavier Cassard, Chirurgien Orthopédique

Using authenticity to adapt to a changing world - Jérémy Malaterre, HR Director, Sandoz France

Auriane Cano-Chancel, Head of Oncology AstraZeneca France - The Revolution of Hope in Oncology

[3min] Pourquoi l'oncologie vit sa 3ème révolution ?

[3min] Pourquoi les médicaments et vaccins d'hier sont toujours essentiels ?

De la recherche de pointe à la direction d'entreprise - Karine Levesque, GM CSL Vifor France

Reinventing models in medical equipment - Nathalie Girard, GM Pari France